MAPT and Alzheimer disease: Although deposition of Aβ and tau has been the center of AD drug development research, many clinical trials on Aβ and tau clearing have been conducted, with disappointing outcomes (Congdon and Sigurdsson, 2018; Huang et al., 2020).